Developer docs
API playgroundTry for free, no card

Search company profiles

BrainScope

Full company profile

uuid0000d5v

Namestring
BrainScope
Legal namestring
BrainScope Company Inc
Websiteurl
brainscope.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

BrainScope is a private, Maryland-based medical neurotechnology company that develops and commercializes a handheld, FDA-cleared AI/ML-enabled EEG device (BrainScope One) and accompanying disposable electrode headsets for objective assessment of mild traumatic brain injury and concussion. The device runs proprietary AI-derived algorithms (Structural Injury Classifier, Brain Function Index, and Concussion Index) on EEG signals to identify likely brain bleeds (99% sensitivity to intracranial blood of at least 1 mL, 98% NPV) and concussions (86% sensitivity, 71% specificity, 90% NPV in JAMA Network Open 2021 validation), with results designed for upload to the electronic medical record. BrainScope's primary commercial segments are U.S. hospital emergency departments, urgent care, and U.S. Department of Defense / federal customers (sold via RedOne Medical SDVOSB channel with NSN-listed device and headset), with secondary use in collegiate and high school athletic programs.

The company generates revenue through one-time sales of the BrainScope hardware under quote-based purchase orders with net-30 terms and recurring sales of single-use disposable electrode headsets, supplemented by extended warranty and post-sale support. In June 2025, BrainScope launched its Large Neural Model Platform, an in-house LLM-style deep learning foundation model applied to EEG, intended to enable a pipeline of new CNS biomarkers for Alzheimer's disease, ARIA detection, stroke, and clinical trial enrichment, funded in part by the Alzheimer's Drug Discovery Foundation. Recent strategic emphasis is on scaling commercialization under a new CEO (Matt Adams, Nov 2025), new VP of Sales (David Wingate, 2026), and an expanded Board including ex-Medtronic and Aon representation.

The company has raised approximately $35 million from Aon plc (2021) plus prior grants and equity from Maryland Venture Fund, NFL/GE, Revolution (Steve Case), and ADDF, and has accumulated more than $27 million in U.S. Department of Defense research contracts. BrainScope holds 83 issued patents, 10 FDA and global clearances, and is led from its Rockville, Maryland headquarters.

Short descriptiontext

BrainScope is a Maryland-based medical neurotechnology company that develops and commercializes a handheld, FDA-cleared AI/ML-enabled EEG device and disposable headsets for objective assessment of mild traumatic brain injury, concussion, and emerging CNS biomarkers for U.S. hospitals, the Department of Defense, and biopharma research customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
EEG medical devices, brain injury assessment, concussion diagnostics, AI-enabled EEG, neurological biomarkers
Industry2 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
EEG-based Brain Injury Diagnostic Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Hardware sales of BrainScope EEG device (Equipment)
TypeHardware Sales
Description

One-time sale of the proprietary BrainScope device (BrainScope 500 Series / BrainScope One) shipped Ex Works (INCOTERMS 2020) under purchase orders; pricing quote-based with net-30 invoice terms.

brainscope.com
2Consumables: disposable electrode headsets
TypeHardware Sales
Description

Recurring revenue from disposable electrode headsets (e.g., Part # AH-3125, Box of 25; NSN 6515-01-665-4357) used with the BrainScope device for each patient assessment.

brainscope.com
3Extended warranty and post-sale support
TypeProfessional Services
Description

Customers may purchase an extended warranty to lengthen the limited 1-year product warranty for Equipment beyond the first year post-delivery; per Standard Purchase Terms.

brainscope.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Pricing details1 tier
1Quote-based enterprise sale of device + consumables under Standard Purchase Terms
ModelOtherBilling cadenceMulti-year contract
Notes

Not publicly disclosed. Customers request a quote and submit a purchase order; pricing is per the applicable Order, plus shipping, taxes and duties. Net 30 payment terms. No returns; deemed accepted on delivery.

brainscope.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1BrainScope One
Description

Flagship FDA-cleared, hand-held, EEG-based medical device for rapid, non-invasive assessment of traumatic brain injury and concussion at the point of care, intended for use in hospital emergency departments, urgent care centers, and other clinical settings.

Core offering1 text field

BrainScope develops and commercializes FDA-cleared, AI/ML-enabled handheld EEG medical devices and proprietary biomarkers for objective assessment of traumatic brain injury (brain bleeds and concussions) at the point of care. Its flagship product, BrainScope One, pairs a ruggedized handheld EEG capture device and disposable electrode headsets with on-device algorithms (Structural Injury Classifier, Concussion Index, Brain Function Index). The company also operates a Large Neural Model deep learning platform extending LLM-style architectures to EEG to develop biomarkers across CNS indications including Alzheimer's disease prediction, stroke, and ARIA monitoring.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • ~50% reduction in unnecessary head CTs reported across major U.S. health systems
+7 more records
Product overview1 text field

BrainScope offers a single unified product — BrainScope One — a handheld, FDA-cleared AI/ML medical device for objective head injury assessment, augmented by a platform-plus-modules architecture. The core hardware device hosts a suite of proprietary AI-derived EEG algorithms (Structural Injury Classifier, Concussion Index, and Brain Function Index) along with digitized neurocognitive assessments (SCAT5, MACE2, PECARN, NPC), and pairs with a disposable electrode headset accessory. Underpinning future biomarker development is the Large Neural Model Platform, a deep learning platform that applies LLM-style architectures to EEG data and currently powers research efforts such as an early Alzheimer's prediction biomarker. Together, the BrainScope One device, its on-device AI modules, the disposable headset, and the Large Neural Model platform form an integrated EEG-based brain assessment and biomarker discovery offering targeted at clinical, military, and research users.

Product and service4 records
1BrainScope One
CategoryCore medical device product
2BrainScope Disposable Electrode Headset
CategoryConsumable / accessory
3Large Neural Model Platform
CategoryAI platform / biomarker development
4Early Alzheimer's Prediction Biomarker (Proof-of-Concept)
CategoryNeurological biomarker (research / pre-commercial)
Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierStrategic Advisor (Board-Level)TypeStrategic or Co-development PartnerAnnounced on2025-06-11
Description

Mike Genau, former President of Medtronic's Americas Region (a $7B business unit), joined BrainScope's Board of Directors in June 2025, bringing MedTech scaling and commercial strategy expertise.

2Ralph Terkowitz (Board Chairman)
Strategic tierStrategic Advisor (Board Chairman)TypeStrategic or Co-development PartnerAnnounced on2025-06-11
Description

Ralph Terkowitz, former General Partner at ABS Capital Partners, elected Chairman of BrainScope's Board in June 2025 (previously on the Board since 2023). Also serves on the Board of The 10,000 Brains Project and is Co-Chairman of The Robert Packard Center for ALS Research at Johns Hopkins.

brainscope.com
Strategic tierClinical Society Endorsement / AlignmentTypeGTM or Marketing PartnerAnnounced on2023-09-19
Description

BrainScope's technology 'supports the American College of Emergency Physicians (ACEP) Choosing Wisely® campaign to avoid CT scans of the head in emergency department patients with minor head injury' (per 2021 JAMA release). CMS CQM #415 is also used to align messaging around head CT reduction.

Strategic tierCore Channel Partner (Federal / Military)TypeChannel Partner/ Reseller/ Distributor
Description

CVE-certified Service-Disabled Veteran-Owned Small Business that sources innovative medical devices and pharmaceuticals for the federal marketplace. Lists BrainScope Device 500 Series (Part # BSO-2001, NSN 6515-01-655-4480) and Disposable Electrode Headsets (Part # AH-3125, NSN 6515-01-665-4357). Cage Code 71UG3; ECAT, DAPA, VA FSS in progress.

Strategic tierResearch Collaboration PartnerTypeStrategic or Co-development Partner
Description

Lead author Dr. Jeffrey Bazarian (Department of Emergency Medicine, University of Rochester School of Medicine) led the JAMA Network Open 2021 study; Dr. Leslie Prichep, CSO of BrainScope, co-authored. Studies conducted 2017-2019 across 49 high schools, colleges, and concussion clinics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Ceribell develops AI-enabled point-of-care EEG devices for hospital use (including emergency and ICU settings) for rapid brain monitoring and seizure detection. Directly comparable to BrainScope as a fellow AI-EEG neurology medical device company targeting U.S. health systems with FDA-cleared hardware and cloud-connected software.

TypeDirect peer
Description

Wave Neuroscience offers EEG-based diagnostic and treatment platforms for brain injury, PTSD, and other neurological conditions. Comparable to BrainScope as a direct competitor in the EEG-based brain health and head injury assessment space with overlapping clinical indications.

TypeBroad incumbent
Description

Natus Medical is a long-established neurodiagnostic medical device company offering a broad portfolio of EEG, EMG, and sleep diagnostic equipment to hospitals and clinics. Comparable to BrainScope as an incumbent in the same neurology/EEG device category serving U.S. health systems, though with a much wider product portfolio.

TypeBroad incumbent
Description

Compumedics manufactures EEG, sleep diagnostic, and brain monitoring equipment used in hospitals and research settings globally. Comparable to BrainScope as an established neurodiagnostics player with overlapping EEG hardware and clinical applications.

TypeBroad incumbent
Description

Cadwell is a privately held neurodiagnostic device maker offering EEG, EMG, and intraoperative monitoring products to hospitals and neurology practices. Comparable to BrainScope as an EEG-focused neurology device company serving similar hospital and clinical customers.

TypeEmerging player
Description

iRhythm Technologies applies AI/ML to cardiac ambulatory monitoring (Zio patch), demonstrating a parallel commercial playbook of combining a proprietary wearable sensor with cloud-based AI diagnostics in a hospital-prescribed workflow. Conceptually comparable to BrainScope's hardware-plus-AI biomarker model, though in cardiology rather than neurology.

TypeBroad incumbent
Description

Medtronic is a global MedTech leader with a significant neuroscience division (formerly Covidien) covering brain monitoring, neuromodulation, and neurosurgery. BrainScope's VP Sales and Board member both came from Medtronic, underscoring Medtronic as a relevant benchmark and potential strategic acquirer or competitor in the neurodiagnostics space.

TypeBroad incumbent
Description

GE HealthCare is a major medical imaging and diagnostics company with EEG and patient monitoring offerings, and through the GE-NFL Head Health Challenge has been a direct grant partner to BrainScope. Comparable as a broader incumbent in hospital neurodiagnostics that could compete or partner with BrainScope's AI-EEG platform.

TypeBroad incumbent
Description

Philips offers a portfolio of patient monitoring and neurology solutions (including EEG) to hospitals globally. Comparable to BrainScope as a large incumbent with overlapping neurodiagnostic hospital sales channels and the ability to bundle EEG into broader capital sales.

TypeEmerging player
Description

Emotiv develops consumer and research-grade EEG headsets with cloud-based AI analytics for brain-computer interface and wellness applications. Comparable to BrainScope as an EEG hardware-plus-AI platform player, though serving research and consumer segments rather than the FDA-regulated clinical market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BrainScope

EEG-based Brain Injury Diagnostic Medical Devicesbrainscope.com

BrainScope is a Maryland-based medical neurotechnology company that develops and commercializes a handheld, FDA-cleared AI/ML-enabled EEG device and disposable headsets for objective assessment of mild traumatic brain injury, concussion, and emerging CNS biomarkers for U.S. hospitals, the Department of Defense, and biopharma research customers.

What BrainScope does

BrainScope is a private, Maryland-based medical neurotechnology company that develops and commercializes a handheld, FDA-cleared AI/ML-enabled EEG device (BrainScope One) and accompanying disposable electrode headsets for objective assessment of mild traumatic brain injury and concussion. The device runs proprietary AI-derived algorithms (Structural Injury Classifier, Brain Function Index, and Concussion Index) on EEG signals to identify likely brain bleeds (99% sensitivity to intracranial blood of at least 1 mL, 98% NPV) and concussions (86% sensitivity, 71% specificity, 90% NPV in JAMA Network Open 2021 validation), with results designed for upload to the electronic medical record. BrainScope's primary commercial segments are U.S. hospital emergency departments, urgent care, and U.S. Department of Defense / federal customers (sold via RedOne Medical SDVOSB channel with NSN-listed device and headset), with secondary use in collegiate and high school athletic programs.

The company generates revenue through one-time sales of the BrainScope hardware under quote-based purchase orders with net-30 terms and recurring sales of single-use disposable electrode headsets, supplemented by extended warranty and post-sale support. In June 2025, BrainScope launched its Large Neural Model Platform, an in-house LLM-style deep learning foundation model applied to EEG, intended to enable a pipeline of new CNS biomarkers for Alzheimer's disease, ARIA detection, stroke, and clinical trial enrichment, funded in part by the Alzheimer's Drug Discovery Foundation. Recent strategic emphasis is on scaling commercialization under a new CEO (Matt Adams, Nov 2025), new VP of Sales (David Wingate, 2026), and an expanded Board including ex-Medtronic and Aon representation.

The company has raised approximately $35 million from Aon plc (2021) plus prior grants and equity from Maryland Venture Fund, NFL/GE, Revolution (Steve Case), and ADDF, and has accumulated more than $27 million in U.S. Department of Defense research contracts. BrainScope holds 83 issued patents, 10 FDA and global clearances, and is led from its Rockville, Maryland headquarters.

BrainScope firmographics

Firmographics
Name
BrainScope
Legal name
BrainScope Company Inc
Website
https://brainscope.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
BrainScope is a Maryland-based medical neurotechnology company that develops and commercializes a handheld, FDA-cleared AI/ML-enabled EEG device and disposable headsets for objective assessment of mild traumatic brain injury, concussion, and emerging CNS biomarkers for U.S. hospitals, the Department of Defense, and biopharma research customers.
Ownership category
akta.pro rank

BrainScope industry classification

Industry
Product category
EEG-based Brain Injury Diagnostic Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • EEG medical devices
  • Brain injury assessment
  • Concussion diagnostics
  • AI-enabled EEG
  • Neurological biomarkers

Where BrainScope is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

BrainScope business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Hardware sales of BrainScope EEG device (Equipment): One-time sale of the proprietary BrainScope device (BrainScope 500 Series / BrainScope One) shipped Ex Works (INCOTERMS 2020) under purchase orders; pricing quote-based with net-30 invoice terms.
  2. Consumables: disposable electrode headsets: Recurring revenue from disposable electrode headsets (e.g., Part # AH-3125, Box of 25; NSN 6515-01-665-4357) used with the BrainScope device for each patient assessment.
  3. Extended warranty and post-sale support: Customers may purchase an extended warranty to lengthen the limited 1-year product warranty for Equipment beyond the first year post-delivery; per Standard Purchase Terms.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise sale of device + consumables under Standard Purchase Terms

Go-to-market motion3 records

Distribution channels3 records

Marketing channels10 records

BrainScope product offering

Product offering

Core offering

BrainScope develops and commercializes FDA-cleared, AI/ML-enabled handheld EEG medical devices and proprietary biomarkers for objective assessment of traumatic brain injury (brain bleeds and concussions) at the point of care. Its flagship product, BrainScope One, pairs a ruggedized handheld EEG capture device and disposable electrode headsets with on-device algorithms (Structural Injury Classifier, Concussion Index, Brain Function Index). The company also operates a Large Neural Model deep learning platform extending LLM-style architectures to EEG to develop biomarkers across CNS indications including Alzheimer's disease prediction, stroke, and ARIA monitoring.

Product overview

BrainScope offers a single unified product — BrainScope One — a handheld, FDA-cleared AI/ML medical device for objective head injury assessment, augmented by a platform-plus-modules architecture. The core hardware device hosts a suite of proprietary AI-derived EEG algorithms (Structural Injury Classifier, Concussion Index, and Brain Function Index) along with digitized neurocognitive assessments (SCAT5, MACE2, PECARN, NPC), and pairs with a disposable electrode headset accessory. Underpinning future biomarker development is the Large Neural Model Platform, a deep learning platform that applies LLM-style architectures to EEG data and currently powers research efforts such as an early Alzheimer's prediction biomarker. Together, the BrainScope One device, its on-device AI modules, the disposable headset, and the Large Neural Model platform form an integrated EEG-based brain assessment and biomarker discovery offering targeted at clinical, military, and research users.

Differentiator

Problem solved

Functional benefit

Brands

  • BrainScope One: Flagship FDA-cleared, hand-held, EEG-based medical device for rapid, non-invasive assessment of traumatic brain injury and concussion at the point of care, intended for use in hospital emergency departments, urgent care centers, and other clinical settings.

Products and services

  • BrainScope One
  • BrainScope Disposable Electrode Headset
  • Large Neural Model Platform
  • Early Alzheimer's Prediction Biomarker (Proof-of-Concept)

Quantifiable outcome

  • ~50% reduction in unnecessary head CTs reported across major U.S. health systems
  • +7 more outcomes

Companies that use BrainScope

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles5 records

BrainScope technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature8 records

BrainScope partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered strategic advisor (board-level), strategic advisor (board chairman), clinical society endorsement / alignment, core channel partner (federal / military) and research collaboration partner.

  • Medtronic (Board representation - Mike Genau)strategic advisor (board-level)Strategic or Co-development Partner · 11 June 2025Mike Genau, former President of Medtronic's Americas Region (a $7B business unit), joined BrainScope's Board of Directors in June 2025, bringing MedTech scaling and commercial strategy expertise.
  • Ralph Terkowitz (Board Chairman)strategic advisor (board chairman)Strategic or Co-development Partner · 11 June 2025Ralph Terkowitz, former General Partner at ABS Capital Partners, elected Chairman of BrainScope's Board in June 2025 (previously on the Board since 2023). Also serves on the Board of The 10,000 Brains Project and is Co-Chairman of The Robert Packard Center for ALS Research at Johns Hopkins.
  • ACEP (American College of Emergency Physicians) Choosing Wisely Campaignclinical society endorsement / alignmentGTM or Marketing Partner · 19 September 2023BrainScope's technology 'supports the American College of Emergency Physicians (ACEP) Choosing Wisely® campaign to avoid CT scans of the head in emergency department patients with minor head injury' (per 2021 JAMA release). CMS CQM #415 is also used to align messaging around head CT reduction.
  • RedOne Medical (SDVOSB)core channel partner (federal / military)Channel Partner/ Reseller/ DistributorCVE-certified Service-Disabled Veteran-Owned Small Business that sources innovative medical devices and pharmaceuticals for the federal marketplace. Lists BrainScope Device 500 Series (Part # BSO-2001, NSN 6515-01-655-4480) and Disposable Electrode Headsets (Part # AH-3125, NSN 6515-01-665-4357). Cage Code 71UG3; ECAT, DAPA, VA FSS in progress.
  • University of Rochester / Lead academic investigators (Concussion Index validation)research collaboration partnerStrategic or Co-development PartnerLead author Dr. Jeffrey Bazarian (Department of Emergency Medicine, University of Rochester School of Medicine) led the JAMA Network Open 2021 study; Dr. Leslie Prichep, CSO of BrainScope, co-authored. Studies conducted 2017-2019 across 49 high schools, colleges, and concussion clinics.

Scale indicators15 records

Recent moves6 records

Expansion highlights7 records

BrainScope competitors and assessment

Company assessment

Direct peers

  • Ceribell: Ceribell develops AI-enabled point-of-care EEG devices for hospital use (including emergency and ICU settings) for rapid brain monitoring and seizure detection. Directly comparable to BrainScope as a fellow AI-EEG neurology medical device company targeting U.S. health systems with FDA-cleared hardware and cloud-connected software.
  • Wave Neuroscience (formerly Mind Research Network / Neuropathix): Wave Neuroscience offers EEG-based diagnostic and treatment platforms for brain injury, PTSD, and other neurological conditions. Comparable to BrainScope as a direct competitor in the EEG-based brain health and head injury assessment space with overlapping clinical indications.

Broad incumbents

  • Natus Medical: Natus Medical is a long-established neurodiagnostic medical device company offering a broad portfolio of EEG, EMG, and sleep diagnostic equipment to hospitals and clinics. Comparable to BrainScope as an incumbent in the same neurology/EEG device category serving U.S. health systems, though with a much wider product portfolio.
  • Compumedics: Compumedics manufactures EEG, sleep diagnostic, and brain monitoring equipment used in hospitals and research settings globally. Comparable to BrainScope as an established neurodiagnostics player with overlapping EEG hardware and clinical applications.
  • Cadwell Industries: Cadwell is a privately held neurodiagnostic device maker offering EEG, EMG, and intraoperative monitoring products to hospitals and neurology practices. Comparable to BrainScope as an EEG-focused neurology device company serving similar hospital and clinical customers.
  • Medtronic: Medtronic is a global MedTech leader with a significant neuroscience division (formerly Covidien) covering brain monitoring, neuromodulation, and neurosurgery. BrainScope's VP Sales and Board member both came from Medtronic, underscoring Medtronic as a relevant benchmark and potential strategic acquirer or competitor in the neurodiagnostics space.
  • GE HealthCare: GE HealthCare is a major medical imaging and diagnostics company with EEG and patient monitoring offerings, and through the GE-NFL Head Health Challenge has been a direct grant partner to BrainScope. Comparable as a broader incumbent in hospital neurodiagnostics that could compete or partner with BrainScope's AI-EEG platform.
  • Philips (Royal Philips): Philips offers a portfolio of patient monitoring and neurology solutions (including EEG) to hospitals globally. Comparable to BrainScope as a large incumbent with overlapping neurodiagnostic hospital sales channels and the ability to bundle EEG into broader capital sales.

Emerging players

  • iRhythm Technologies: iRhythm Technologies applies AI/ML to cardiac ambulatory monitoring (Zio patch), demonstrating a parallel commercial playbook of combining a proprietary wearable sensor with cloud-based AI diagnostics in a hospital-prescribed workflow. Conceptually comparable to BrainScope's hardware-plus-AI biomarker model, though in cardiology rather than neurology.
  • Emotiv: Emotiv develops consumer and research-grade EEG headsets with cloud-based AI analytics for brain-computer interface and wellness applications. Comparable to BrainScope as an EEG hardware-plus-AI platform player, though serving research and consumer segments rather than the FDA-regulated clinical market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

BrainScope social profiles

Digital presence

BrainScope financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BrainScope leadership team

Management profile

Number of profiles

Profiles11 records

BrainScope funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BrainScope M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BrainScope

What does BrainScope do?

BrainScope develops and commercializes FDA-cleared, AI/ML-enabled handheld EEG medical devices and proprietary biomarkers for objective assessment of traumatic brain injury (brain bleeds and concussions) at the point of care. Its flagship product, BrainScope One, pairs a ruggedized handheld EEG capture device and disposable electrode headsets with on-device algorithms (Structural Injury Classifier, Concussion Index, Brain Function Index). The company also operates a Large Neural Model deep learning platform extending LLM-style architectures to EEG to develop biomarkers across CNS indications including Alzheimer's disease prediction, stroke, and ARIA monitoring.

Is BrainScope a public or private company?

BrainScope is a private company. It is classified as venture growth investor backed and is currently operating.

When was BrainScope founded?

BrainScope was founded in 2010. It employs 11 to 50 people.

Where is BrainScope based?

BrainScope is headquartered in Rockville, United States, in the North America region.

How does BrainScope make money?

Three revenue lines are on record. Hardware sales of BrainScope EEG device (Equipment) is the primary driver. The others are consumables: disposable electrode headsets and extended warranty and post-sale support.

Who are BrainScope's main competitors?

Direct peers on record are Ceribell and Wave Neuroscience (formerly Mind Research Network / Neuropathix). Broad incumbents are Natus Medical, Compumedics, Cadwell Industries, Medtronic, GE HealthCare and Philips (Royal Philips). Emerging players are iRhythm Technologies and Emotiv.

Does BrainScope have an API?

No public API is recorded for BrainScope.

What industry is BrainScope in?

BrainScope's product category is EEG-based Brain Injury Diagnostic Medical Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLALAGAC, Neurology Telemedicine Platforms. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizBrainScope Appoints David Wingate to Lead Sales and Commercial OperationsBrainScope has appointed David Wingate as vice president of sales and commercial operations to lead commercialization of its AI-enabled concussion and brain injury assessment platform. Wingate brings over 30 years of healthcare and medical device experience, having previously served as VP of U.S. sales at Accelus and held senior leadership roles at Medtronic's neuroscience business. The appointment supports BrainScope's strategy to expand its FDA-cleared technology beyond core head injury assessments into broader neurological conditions including Alzheimer's disease.AiThorityBrainScope Strengthens Executive Team With Veteran Commercial Leader David WingateBrainScope, an AI-enabled brain health assessment company, announced the appointment of David Wingate as Vice President of Sales and Commercial Operations. Wingate brings more than three decades of healthcare leadership, including prior roles at Medtronic managing over $300 million in annual sales and most recently as VP of U.S. Sales at Accelus. The company stated this appointment is intended to accelerate commercial adoption of its FDA-cleared AI-enabled EEG technology for concussion and brain injury assessment, as well as expand into new indications including Alzheimer's disease.BioSpaceBrainScope Strengthens Executive Team With Veteran Commercial Leader David WingateBrainScope appointed David Wingate as Vice President of Sales and Commercial Operations. He brings over three decades of healthcare leadership, including roles at Accelus and Medtronic. He will lead commercial strategy and accelerate adoption of BrainScope's AI-enabled brain health technologies.citybizBrainScope Names David Wingate VP of Sales and Commercial OperationsBrainScope, a commercial-stage neurotechnology company, has appointed David Wingate as Vice President of Sales and Commercial Operations to lead its commercial strategy and expand market adoption of its FDA-cleared AI-enabled brain health assessment platform. Wingate brings over 30 years of healthcare and medical device experience, most recently serving as VP of U.S. Sales at Accelus and previously holding regional VP positions at Medtronic's neuroscience division overseeing more than $300 million in annual sales. The appointment is expected to support commercialization of BrainScope's expanding pipeline, which includes applications for concussion assessment, structural brain injury, and Alzheimer's disease biomarkers.GlobeNewswireBrain Artificial Intelligence Assisted Diagnosis Solution Report 2025: Market to Hit $5.46 Billion by 2029 as Neuroimaging and Preventive Digital Health Accelerate Adoption - Forecast to 2034Research and Markets released a report forecasting the global brain AI-assisted diagnosis solution market to grow from $2.19 billion in 2025 to $5.46 billion by 2029, driven by rising neurological disorders and healthcare digitization. Key industry developments include BrainScope Company Inc.'s launch of a new deep learning platform for EEG analysis and SyntheticMR AB's acquisition of Combinostics Oy to expand its neuroimaging portfolio.Mpo-magBrainScope Appoints Matt Adams CEOBrainScope, a neurotechnology company specializing in brain diagnostics, has appointed Matt Adams as its new CEO, succeeding Laurie Silver who will become president and remain on the board of directors. Adams brings over 20 years of medtech experience with a track record of delivering over $1.3 billion in shareholder value through diagnostics, devices, and therapeutics leadership. Under Silver's two-year tenure, the company increased brain injury assessment revenue by 50% year-over-year and developed a multimodal deep learning platform for central nervous system disorders.LinkedInMoberg Analytics Secures $600,000 to Accelerate Commercialization of Its Brain Monitoring PlatformMedTech company BrainScope has appointed Matt Adams, a medtech veteran with over 20 years of experience scaling companies, as its new CEO, signaling a strategic shift from foundational R&D toward global commercial execution. The company's FDA-cleared AI-powered EEG headset for triaging traumatic brain injuries is being prepared for aggressive expansion into high-growth international markets, particularly the Asia-Pacific region. BrainScope is also leveraging next-generation deep learning platforms and proof-of-concept biomarkers to extend beyond concussion diagnosis into tackling Alzheimer's disease and other neurodegenerative conditions.openPR.comTraumatic Brain Injury Assessment & Management Devices Market Set to Witness Significant Growth by 2033 | BrainScope Company, Inc., Integra LifeSciences, NanoDx, Inc., Natus Medical Incorporated.The global Traumatic Brain Injury Assessment & Management Devices Market is projected to grow from $1.1 billion in 2024 to $2.8 billion by 2033, a CAGR of 11.5%. Growth is driven by rising head injuries and technological advancements, with key players including BrainScope, Integra LifeSciences, and NanoDx.SyrSinger becomes executive board chair at BrainScopeMichael Singer was named executive chairman of BrainScope, a company developing remote assessment devices for brain-related injuries. He previously served as CEO since the company's founding, overseeing eight DoD research contracts, the first FDA-cleared traumatic brain injury product, and over 20 clinical studies.